A Phase 1b Study of TAK-659 in Combination With NKTR-214 in Patients With Advanced Non-Hodgkin Lymphoma
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Bempegaldesleukin (Primary) ; TAK 659 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Takeda
- 10 Dec 2018 Status changed from planning to not yet recruiting.
- 02 May 2018 New trial record
- 24 Apr 2018 According to a Nektar Therapeutics media release, the company plans to initiate this study in the second half of 2018.